Your search returned 7 results.

Results
	1.	A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. [electronic resource] by Golor, Georg Hu, Ke Ruffin, Matthieu Buchelt, Alexandra Bouillaud, Emmanuel Wang, Yanfeng Maldonado, Mario Producer: 20120827 In: Drug design, development and therapy vol. 6 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study. [electronic resource] by Dietrich, Hartmut Hu, Ke Ruffin, Matthieu Song, Dongweon Bouillaud, Emmanuel Wang, Yanfeng Hasskarl, Jens Producer: 20120625 In: European journal of endocrinology vol. 166 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study. [electronic resource] by Horsmans, Yves Hu, Ke Ruffin, Matthieu Wang, Ying Song, Dongweon Bouillaud, Emmanuel Wang, Yanfeng Mazur, Dago Botha, Frans-Peter Heuman, Douglas M Producer: 20120727 In: Journal of clinical pharmacology vol. 52 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. [electronic resource] by Sheppard, Michael Bronstein, Marcello D Freda, Pamela Serri, Omar De Marinis, Laura Naves, Luciana Rozhinskaya, Liudmila Hermosillo Reséndiz, Karina Ruffin, Matthieu Chen, YinMiao Colao, Annamaria Producer: 20160407 In: Pituitary vol. 18 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. [electronic resource] by Sheppard, Michael Bronstein, Marcello D Freda, Pamela Serri, Omar De Marinis, Laura Naves, Luciana Rozhinskaya, Liudmila Hermosillo Reséndiz, Karina Ruffin, Matthieu Chen, YinMiao Colao, Annamaria Producer: 20150911 In: Pituitary vol. 18 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. [electronic resource] by Bronstein, Marcello D Fleseriu, Maria Neggers, Sebastian Colao, Annamaria Sheppard, Michael Gu, Feng Shen, Chiung-Chyi Gadelha, Mônica Farrall, Andrew J Hermosillo Reséndiz, Karina Ruffin, Matthieu Chen, YinMiao Freda, Pamela Producer: 20161019 In: BMC endocrine disorders vol. 16 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	7.	Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. [electronic resource] by Petersenn, Stephan Farrall, Andrew J De Block, Christophe Block, Christophe Melmed, Shlomo Schopohl, Jochen Caron, Philippe Cuneo, Ross Kleinberg, David Colao, Annamaria Ruffin, Matthieu Hermosillo Reséndiz, Karina Hughes, Gareth Hu, Ke Barkan, Ariel Producer: 20141113 In: Pituitary vol. 17 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)